查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1901484

脓疱疮治疗市场：依给药途径、病患类型、药物类别、配销通路、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Impetigo Treatment Market, By Route of Administration, By Patient Type, By Drug Class, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 365 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年脓疱疮治疗市场规模为 7.78 亿美元，从 2025 年到 2032 年将以 5.8% 的复合年增长率成长。

脓疱疮治疗市场涵盖用于治疗脓疱疮的药品、外用抗生素、消毒剂和先进的皮肤科解决方案。脓疱疮是一种传染性细菌性皮肤感染，主要影响儿童。与卫生条件差、人口拥挤和细菌抗药性增强相关的皮肤感染日益普遍，是推动市场成长的主要因素。一个关键的市场趋势是转向非抗生素和消毒剂疗法，这反映了全球对抗抗菌素抗药性的努力。然而，市场面临抗甲氧西林金黄色葡萄球菌（MRSA）感染日益增多的严峻挑战，MRSA 会降低传统抗生素的疗效，并使治疗方案复杂化。儘管如此，联合疗法、新型外用製剂和速效抗菌剂的创新带来了巨大的机会，使治疗方案更具针对性且不易产生抗药性。随着医疗保健系统将皮肤感染控制和更有效的抗菌药物使用放在首位，这些因素共同推动了脓疱疮治疗市场的稳定成长。

脓疱疮治疗市场－市场动态

日益重视高级皮肤病学和传染病管理

抗生素抗药性和皮肤感染盛行率的上升是脓疱疮治疗市场的主要驱动因素。为了确保治疗成功，医疗系统正在优先考虑更快速的诊断、改进的製剂和先进的抗菌解决方案。策略性的产业发展提升了研发能力，从而进一步推动了这一趋势。例如，2020年1月，诺华收购了The Medicines Company，显着增强了其治疗产品线，并展现了该行业致力于开发传染病解决方案的决心。儘管此次收购的重点是inclisiran，但它反映了该行业向高创新产品组合迈进的更大趋势，间接加速了皮肤病学和皮肤感染治疗（包括脓疱疮）领域的进展。

脓疱疮治疗市场区隔分析：

全球脓疱疮治疗市场按给药途径、患者类型、药物类别、配销通路和地区进行细分。

根据给药途径，口服给药在脓疱疮治疗市场中占据重要地位，因为它对中重度感染、復发病例以及局部抗生素治疗无效的情况均有效。阿莫西林-克拉维酸钾、克林霉素和大环内酯类等口服製剂具有全身性作用，有助于消除深层或广泛感染。抗菌药物创新和联合疗法的不断发展也推动了这一领域的需求。 2020年3月，Menlo Therapeutics与Foamix Pharmaceuticals的合併增强了其皮肤病产品组合，间接促进了针对脓疱疮等皮肤疾病的抗生素和抗感染疗法的研发。此类策略联盟增强了研发能力，有助于开发更有效的口服製剂，从而推动该领域向前发展。

按配销通路，医院药房管道仍然至关重要，因为医院需要治疗更多病情严重、传播迅速或免疫功能低下的脓疱疮病例，这些病例需要及时获得经过验证的药物。该管道受益于规范的抗生素管理、专家会诊以及先进的诊断技术。医院皮肤科服务和疫情管理方案的增加也推动了该通路的发展。例如，2021年11月，NovaBay Pharmaceuticals收购了DERMAdoctor，扩大了该公司专注于皮肤科的产品分销管道，包括医院等专业管道。此类企业措施增加了医院药房中皮肤科医生推荐製剂的供应，从而改善了患者获得可靠脓疱疮治疗方案的机会。

脓疱疮治疗市场—地域性洞察

北美地区在脓疱疮治疗市场占据主导地位，这主要归功于细菌性皮肤感染的高发生率以及公众（尤其是儿童）对脓疱疮的广泛认知。该地区拥有先进的医疗保健基础设施、便利的皮肤科医生资源以及完善的医保报销系统。此外，强而有力的政府公共卫生计画以及品牌药和仿製药处方药的广泛供应也加速了市场对脓疱疮治疗的接受度。高水准的医疗保健支出、常规临床筛检以及快速诊断能力都有助于早期发现并有效治疗脓疱疮病例。此外，大型製药公司积极参与皮肤病学研发，尤其是在对抗抗生素抗药性方面，进一步巩固了北美地区的市场领导地位。

美国脓疱疮治疗市场—国家概况

美国是脓疱疮治疗领域最具影响力的市场之一，这得益于其完善的医疗保健基础设施、高度的感染防范意识以及广泛的皮肤科服务。美国细菌性皮肤感染的发生率居高不下，尤其是在儿童族群中，这推动了对局部和口服抗生素的持续需求。此外，美国重视透过常规儿科筛检进行早期诊断，以达到及时有效的治疗。强大的药物创新能力，以及先进的研发实力和简化的监管流程，进一步塑造了这个市场。

例如，2025年6月，赛诺菲的Dupixent（度普利尤单抗）获得FDA批准，用于治疗大疱性类天疱疮，一种发炎性皮肤病。虽然它并非直接治疗脓疱疮，但这一里程碑事件凸显了美国皮肤病学创新领域的蓬勃发展，为治疗相关皮肤感染和改善患者长期预后开闢了新的途径。

目录

第一章：脓疱疮治疗市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
  • 竞争洞察

第三章：脓疱疮治疗市场主要趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场未来趋势

第四章：脓疱疮治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：脓疱疮治疗市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：脓疱疮治疗市场概况

  • 脓疱疮治疗市占率分析，2024 年
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：脓疱疮治疗市场：依给药途径划分

  • 概述
    • 细分市场占有率分析：按给药途径
    • 主题
    • 口服

第八章：脓疱疮治疗市场：依患者类型划分

  • 概述
    • 细分市场占有率分析：按患者类型
    • 孩子们
    • 老年
    • 成年人

第九章：脓疱疮治疗市场：依药物类别划分

  • 概述
    • 细分市场占有率分析：依药物类别划分
    • 头孢菌素
    • 奎诺酮类
    • 磺胺类药物
    • 夫西丹
    • 林可酰胺
    • 青霉素
    • 四环素
    • 其他的

第十章：脓疱疮治疗市场：依配销通路划分

  • 概述
    • 细分市场占有率分析：按患者类型
    • 医院药房
    • 零售药局
    • 网路药局

第十一章：脓疱疮治疗市场：依地域划分

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • その他
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • その他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • その他
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • その他

第十二章：主要供应商分析：脓疱疮治疗产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • GlaxoSmithKline plc
    • Ranbaxy Laboratories Limited
    • Roche Holding AG
    • Karalex Pharma, LLC
    • Teva Pharmaceutical Industries Ltd
    • Pfizer, Inc
    • SANDOZ GmbH
    • NovaBay Pharmaceuticals, Inc.
    • Lupin Limited
    • Leo Pharma A/S
    • Taro Pharmaceutical Industries Ltd
    • Others

第十三章：360度AnalystView

简介目录
Product Code: ANV5842

Impetigo Treatment Market size was valued at US$ 778 Million in 2024, expanding at a CAGR of 5.8% from 2025 to 2032.

The Impetigo Treatment Market includes pharmaceuticals, topical antibiotics, antiseptics, and advanced dermatology solutions for treating impetigo, a contagious bacterial skin infection that primarily affects children. The rising prevalence of skin infections linked to poor hygiene, overcrowding, and increased bacterial resistance is a major driver of market growth. A key market trend is the shift toward non-antibiotic and antiseptic-based therapies, which reflect global efforts to combat antimicrobial resistance. However, the market faces a significant challenge in the form of rising MRSA (methicillin-resistant Staphylococcus aureus) infections, which reduce the efficacy of conventional antibiotics and complicate treatment protocols. Despite this, significant opportunities arise from innovation in combination therapies, novel topical formulations, and faster-acting antimicrobial agents, allowing for more targeted and resistant-free treatment options. Together, these factors position the impetigo treatment market for steady growth as healthcare systems prioritize skin infection control and more effective antimicrobial use.

Impetigo Treatment Market- Market Dynamics

Rising Focus on Advanced Dermatology and Infectious Disease Management

The rise in antibiotic resistance and skin infection prevalence is a major driver of the Impetigo Treatment Market. To ensure successful treatment outcomes, healthcare systems are prioritizing faster diagnostics, improved formulations, and advanced antimicrobial solutions. This trend is bolstered by strategic industry developments that increase research capacity. For example, in January 2020, Novartis' acquisition of The Medicines Company significantly strengthened its therapeutic pipeline and demonstrated the industry's commitment to developing infectious disease solutions. Although the acquisition focused on inclisiran, it reflects a larger push toward high-innovation portfolios, indirectly accelerating progress in dermatology and skin-infection therapeutics, including impetigo.

Impetigo Treatment Market- Segmentation Analysis:

The Global Impetigo Treatment Market is segmented by Route of Administration, Patient Type, Drug Class, Distribution Channel and Region.

According to the Route of Administration, the oral segment is important in the Impetigo Treatment Market because it works well for moderate to severe infections, recurrent cases, and situations where topical antibiotics fail. Oral formulations such as amoxicillin-clavulanate, clindamycin, and macrolides have systemic action, which aids in the elimination of deeper or widespread infections. Growing antimicrobial innovation and combination therapies also contribute to this segment's demand. In March 2020, Menlo Therapeutics' merger with Foamix Pharmaceuticals strengthened its dermatology portfolio, indirectly supporting improved antibiotic and anti-infective therapy development for skin diseases such as impetigo. Such strategic alliances strengthen R&D capabilities for more potent oral formulations, propelling this segment forward.

By Distribution Channel, the hospital pharmacy segment remains critical as hospitals treat more severe, rapidly spreading, or immunocompromised impetigo cases that necessitate prompt access to validated medications. This segment benefits from structured antibiotic stewardship, specialist consultations, and access to advanced diagnostics. The increase in hospital-based dermatology services and outbreak management protocols is also driving the segment. For instance, in November 2021, NovaBay Pharmaceuticals' acquisition of DERMAdoctor expanded the company's dermatology-focused product distribution through professional channels, including hospitals. Such corporate moves increase the availability of dermatologist-recommended formulations in hospital pharmacies, thereby improving patient access to reliable impetigo treatment options.

Impetigo Treatment Market- Geographical Insights

North America commands the Impetigo Treatment Market, owing to the high prevalence of bacterial skin infections and widespread public awareness of impetigo, particularly among children. The region has an advanced healthcare infrastructure, widespread access to dermatologists, and well-established reimbursement systems. In addition, strong government-backed public health programs and widespread availability of both branded and generic prescription medications have accelerated market adoption. A high level of healthcare spending, routine clinical screenings, and rapid diagnostic capabilities all help to detect impetigo cases early and treat them effectively. Additionally, the active involvement of major pharmaceutical companies in dermatology R&D, particularly in the fight against antibiotic resistance, reinforces North America's market leadership.

United States Impetigo Treatment Market- Country Insights

The United States is one of the most influential markets for impetigo treatment, thanks to a robust healthcare infrastructure, high infection awareness, and widespread access to dermatology services. The country experiences a consistent incidence of bacterial skin infections, particularly among children, fueling ongoing demand for topical and oral antibiotics. In addition, the United States prioritizes early diagnosis through routine pediatric screenings, which allows for timely and effective treatment. Strong pharmaceutical innovation, backed up by advanced R&D capabilities and streamlined regulatory pathways, shapes the market even further.

For example, in June 2025, Sanofi received FDA approval for Dupixent (dupilumab) to treat bullous pemphigoid, an inflammatory skin disease. Although not a direct impetigo treatment, this milestone highlights the nation's growing dermatology innovation landscape, opening up new avenues for managing associated skin infections and improving long-term patient outcomes.

Impetigo Treatment Market- Competitive Landscape:

The competitive landscape of the impetigo treatment market is distinguished by the presence of several key players involved in the development, manufacturing, and marketing of antibiotics and other treatment options. Companies are focusing on strategic initiatives like mergers and acquisitions, partnerships, and collaborations to improve their market position and product portfolio. Many companies prioritize the development of new antibiotic formulations and combination therapies as a means of addressing antibiotic resistance and improving treatment outcomes. For instance, in January 2022, Pfizer received approval for CIBINQO (abrocitinib), an oral inhibitor for the treatment of patients with moderate to severe dermatitis. CIBINQO will be an important new oral option for those who have yet to find relief. CIBINQO demonstrated good efficacy in clearing skin, reducing itching, and managing the severity and scope of eczema, with a benefit-risk profile that supports its use in the FDA-approved patient population.

Recent Developments:

In May 2024, NovaBay Pharmaceuticals has launched a dermatology service via telehealth for remote consultation and prescription to treat impetigo. The online service improves access, particularly in rural and underserved markets, by allowing clinicians to diagnose and treat impetigo remotely. The service is part of a trend toward hybrid dermatologic treatment models and allows patients to easily access topically prescribed antibiotics.

In June 2025, Ferrer announced the successful completion of its Phase III trial of Ozenoxacin 1% cream to treat impetigo in pediatric and adult patients, which demonstrated improved clinical and bacteriological responses compared to placebo. The cream showed early improvement on days 3-4 and was well tolerated in geographically dispersed centers in the United States, Germany, South Africa, and Ukraine. With this success, Ozenoxacin moves to the forefront of the near-term global market presence.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL IMPETIGO TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline plc
  • Ranbaxy Laboratories Limited
  • Roche Holding AG
  • Karalex Pharma, LLC
  • Teva Pharmaceutical Industries Ltd
  • Pfizer, Inc
  • SANDOZ GmbH
  • NovaBay Pharmaceuticals, Inc.
  • Lupin Limited
  • Leo Pharma A/S
  • Taro Pharmaceutical Industries Ltd
  • Others

GLOBAL IMPETIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Topical
  • Oral

GLOBAL IMPETIGO TREATMENT MARKET, BY PATIENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Children
  • Elderly
  • Adults

GLOBAL IMPETIGO TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Cephalosporins
  • Quinolones
  • Sulfonamides
  • Fusidane
  • Lincosamide
  • Penicillin
  • Tetracycline
  • Others

GLOBAL IMPETIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL IMPETIGO TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Impetigo Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Impetigo Treatment Market Snippet by Route of Administration
    • 2.1.2. Impetigo Treatment Market Snippet by Patient Type
    • 2.1.3. Impetigo Treatment Market Snippet by Drug Class
    • 2.1.4. Impetigo Treatment Market Snippet by Distribution Channel
    • 2.1.5. Impetigo Treatment Market Snippet by Country
    • 2.1.6. Impetigo Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Impetigo Treatment Key Market Trends

  • 3.1. Impetigo Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Impetigo Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Impetigo Treatment Market Opportunities
  • 3.4. Impetigo Treatment Market Future Trends

4. Impetigo Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Impetigo Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Impetigo Treatment Market Landscape

  • 6.1. Impetigo Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Impetigo Treatment Market - By Route of Administration

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 7.1.2. Topical
    • 7.1.3. Oral

8. Impetigo Treatment Market - By Patient Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
    • 8.1.2. Children
    • 8.1.3. Elderly
    • 8.1.4. Adults

9. Impetigo Treatment Market - By Drug Class

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
    • 9.1.2. Cephalosporins
    • 9.1.3. Quinolones
    • 9.1.4. Sulfonamides
    • 9.1.5. Fusidane
    • 9.1.6. Lincosamide
    • 9.1.7. Penicillin
    • 9.1.8. Tetracycline
    • 9.1.9. Others

10. Impetigo Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Patient Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Impetigo Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Impetigo Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Impetigo Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Impetigo Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Impetigo Treatment Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Impetigo Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Patient Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Impetigo Treatment Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. GlaxoSmithKline plc
    • 12.2.2. Ranbaxy Laboratories Limited
    • 12.2.3. Roche Holding AG
    • 12.2.4. Karalex Pharma, LLC
    • 12.2.5. Teva Pharmaceutical Industries Ltd
    • 12.2.6. Pfizer, Inc
    • 12.2.7. SANDOZ GmbH
    • 12.2.8. NovaBay Pharmaceuticals, Inc.
    • 12.2.9. Lupin Limited
    • 12.2.10. Leo Pharma A/S
    • 12.2.11. Taro Pharmaceutical Industries Ltd
    • 12.2.12. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us